Cyclerion Therapeutics (CYCN) Retained Earnings (2019 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Retained Earnings of -$271.0 million for Q4 2025, down 1.32% year-over-year from -$274.6 million in Q4 2024, and little changed quarter-over-quarter from -$270.2 million in Q3 2025.
Cyclerion Therapeutics (CYCN) Retained Earnings (2019 - 2025) Analysis & Trends
Cyclerion Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$271.0 million for Q4 2025.
- In Q4 2025, Retained Earnings fell 1.32% year-over-year to -$271.0 million; the TTM figure through Dec 2025 stood at -$271.0 million (down 1.32% YoY), while the FY2025 annual figure was -$271.0 million, down 1.32% from the prior year.
- Retained Earnings for Q4 2025 stood at -$271.0 million, roughly flat from -$270.2 million in the prior quarter.
- The five-year high for Retained Earnings was -$12000.0 in Q4 2023, with the low at -$271.0 million in Q4 2025.
- The 5-year median for Retained Earnings is -$260.9 million (2022), against an average of -$191.4 million.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings soared 100.0% in 2023, then tumbled 2229000.0% in 2024.
- Cyclerion Therapeutics' Retained Earnings stood at -$215.1 million in 2021, then slipped by 20.49% to -$259.2 million in 2022, then jumped by 100.0% to -$12000.0 in 2023, then sank by 2229000.0% to -$267.5 million in 2024, then fell by 1.32% to -$271.0 million in 2025.
- Business Quant data shows CYCN's Retained Earnings at -$271.0 million in Q4 2025, -$270.2 million in Q3 2025, and -$269.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | -271.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -271.02 Mn |
| Sep 30, 2025 | -270.22 Mn |
| Jun 30, 2025 | -269.25 Mn |
| Mar 31, 2025 | -268.92 Mn |
| Dec 31, 2024 | -267.49 Mn |
| Sep 30, 2024 | -268.02 Mn |
| Jun 30, 2024 | -267.30 Mn |
| Mar 31, 2024 | -265.96 Mn |
| Dec 31, 2023 | -12,000.00 |
| Sep 30, 2023 | -262.72 Mn |
| Jun 30, 2023 | -270.29 Mn |
| Mar 31, 2023 | -19,000.00 |
| Dec 31, 2022 | -259.15 Mn |
| Sep 30, 2022 | -251.94 Mn |
| Jun 30, 2022 | -25,000.00 |
| Mar 31, 2022 | -228.05 Mn |
| Dec 31, 2021 | -215.08 Mn |
| Sep 30, 2021 | -26,000.00 |
| Jun 30, 2021 | -193.01 Mn |
| Mar 31, 2021 | -27,000.00 |